Crinetics shareholders approve Vertex merger; closing expected Sept 1, 2026

Crinetics Pharmaceuticals, Inc.

Merger adoption approved: 79,240,098 for, 13,618 against, 10,915 abstain.
Quorum of 74.71% (79,264,631 of 106,095,205 shares) represented at special meeting.
Non-binding advisory compensation proposal rejected: 33,854,149 for, 44,803,403 against.
Advisory vote failure not a condition; final closing condition now satisfied.
Closing of Vertex acquisition expected on or about September 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.